In the last trading session, 1.16 million Twist Bioscience Corp (NASDAQ:TWST) shares changed hands as the company’s beta touched 2.13. With the company’s per share price at $40.81 changed hands at -$0.39 or -0.95% during last session, the market valuation stood at $2.43B. TWST’s last price was a discount, traded about -49.23% off its 52-week high of $60.90. The share price had its 52-week low at $27.41, which suggests the last value was 32.84% up since then.
Analysts gave the Twist Bioscience Corp (TWST) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.77. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TWST as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Twist Bioscience Corp’s EPS for the current quarter is expected to be -0.57.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Instantly TWST was in red as seen at the end of in last trading. With action -12.61%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -12.18%, with the 5-day performance at -12.61% in the red. However, in the 30-day time frame, Twist Bioscience Corp (NASDAQ:TWST) is -24.52% down.
The consensus price target for the stock as assigned by Wall Street analysts is 56, meaning bulls need an upside of 27.12% from its current market value. According to analyst projections, TWST’s forecast low is 54 with 58 as the target high. To hit the forecast high, the stock’s price needs a -42.12% plunge from its current level, while the stock would need to soar -32.32% for it to hit the projected low.
Twist Bioscience Corp (TWST) estimates and forecasts
Year-over-year growth is forecast to reach 20.16% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 92M. 10 analysts are of the opinion that Twist Bioscience Corp’s revenue for the current quarter will be 95.71M. The company’s revenue for the corresponding quarters a year ago was 75.3M and 81.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 22.18%. The estimates for the next quarter sales put growth at 17.48%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.70%. The 2025 estimates are for Twist Bioscience Corp earnings to increase by 43.45%, but the outlook for the next 5-year period is at 37.54% per year.
TWST Dividends
Twist Bioscience Corp is expected to release its next quarterly earnings report in March.
ARTISAN PARTNERS LIMITED PARTNERSHIP holds the second largest percentage of outstanding shares, with 10.4371% or 6.07 million shares worth $299.06 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF . With 3.06 shares estimated at $125.05 million under it, the former controlled 5.14% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held about 3.62% of the shares, roughly 2.16 shares worth around $88.11 million.
